* Core Laboratories Inc CLB.N CLB is expected to show a
fall
in quarterly revenue when it reports results on April 24 for
the period ending March 31 2024
* The Houston Texas-based company is expected to report a
3.0% decrease in revenue to $124.442 million from $128.36
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.The company's guidance on January
31 2024, for the period ended March 31, was for revenue between
$122.00 million and $128.00 million.
* LSEG's mean analyst estimate for Core Laboratories Inc is
for
earnings of 16 cents per share. The company's EPS guidance on
January 31 2024, for the period ended March 31, was between
$0.14 and $0.18
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
Inc is $17.50, above its last closing price of $16.97.
The company's guidance on January 31 2024 for the period ended
March 31 was for Earnings before Interest and Taxes between
USD11.8 million and USD14.3 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.19 0.19 0.19 Met -1.3
Sep. 30 2023 0.22 0.22 0.22 Met -0.1
Jun. 30 2023 0.20 0.20 0.21 Beat 5.3
Mar. 31 2023 0.16 0.16 0.19 Beat 20.3
Dec. 0.19 0.20 0.20 Met 2.2
31 2022
Sep. 30 2022 0.15 0.15 0.18 Beat 20.3
Jun. 30 2022 0.12 0.14 0.12 Missed -12
Mar. 31 2022 0.07 0.09 0.08 Missed -11.6
This summary was machine generated April 22 at 22:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)